CJC-1295/Ipamorelin

CJC-1295 + Ipamorelin blend

Growth HormoneNot ApprovedPhase IIResearchSubQ

Popular for:Growth hormone release, body composition, anti-aging

2

Registered Trials

0

Trial Publications

0

PubMed References

Phase II

Evidence Level

Overview

CJC-1295 and Ipamorelin are two distinct peptides frequently stacked together to synergistically enhance growth hormone (GH) release. The short version: people usually care about it for growth hormone release, body composition, anti-aging, but the strength of the evidence depends heavily on indication and study type.

CJC-1295 and Ipamorelin are two distinct peptides frequently stacked together to synergistically enhance growth hormone (GH) release. They work through complementary pathways — CJC-1295 mimics GHRH (growth hormone-releasing hormone) while Ipamorelin mimics ghrelin — creating a more robust and physiologic GH response than either alone.

**CJC-1295: **A synthetic analogue of GHRH (growth hormone-releasing hormone 1-29), also called Modified GRF (1-29) or Mod GRF. Comes in two forms: CJC-1295 without DAC (no Drug Affinity Complex, shorter half-life ~30 min) and CJC-1295 with DAC (extended half-life ~8 days via albumin binding). The 'no DAC' version is preferred in the stack because it produces discrete GH pulses rather than sustained elevation.

**Ipamorelin: **A synthetic pentapeptide ghrelin mimetic and growth hormone secretagogue (GHS). It selectively stimulates GH release through the GHS receptor (GHSR) without significantly raising cortisol, prolactin, or ACTH — making it the cleanest GH secretagogue available. Half-life is approximately 2 hours.

Research Snapshot

What the evidence says

Phase II

CJC-1295/Ipamorelin currently shows 2 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 0 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.

Known vs uncertain

Known signals

  • 2 registered trials are tracked from ClinicalTrials.gov intervention records.
  • 0 PubMed clinical-trial publications are indexed.
  • 0 PubMed randomized controlled trial publications are indexed.
  • 0 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.

Open questions

  • Evidence strength may vary by indication, route, formulation, and population.
  • Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
  • Regulatory status and compounding access can change independently from the research literature.

Mechanism of Action

CJC-1295 (GHRH pathway) provides the 'background signal' telling the pituitary to produce GH, while Ipamorelin (ghrelin pathway) triggers the acute 'release pulse.' Together they amplify the GH response beyond what either achieves alone, wh

Key Research Benefits

Sustained GH and IGF-1 elevation: CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 levels in healthy adults (Ionescu & Bhatt, 2006). No serious adverse reactions were reported.
Selective GH release (Ipamorelin): Does not significantly raise cortisol, prolactin, or ghrelin at therapeutic doses — unlike GHRP-6 or GHRP-2 which spike appetite and cortisol.
Body composition: GH/IGF-1 elevation promotes fat loss (especially visceral fat), lean mass preservation, and improved recovery.
Sleep quality: GH pulse enhancement at bedtime may improve deep sleep (Stage 3/4 NREM), which is when natural GH release peaks.
Recovery and injury healing: Enhanced GH supports collagen synthesis, tendon/ligament repair, and overall tissue recovery.
Skin and hair: Improved skin elasticity, reduced wrinkles, and potentially enhanced hair quality through GH-mediated collagen production.

Clinical Evidence Summary

Combination Product

CJC-1295/Ipamorelin is a commonly paired combination. No clinical studies exist for this specific combination. Research data reflects studies of CJC-1295 and Ipamorelin individually. See each component's page for detailed evidence.

CJC-1295Ipamorelin

- Ionescu & Bhatt (2006) — CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults (2-10 fold increases in GH AUC). No serious adverse events reported. Published in J Clinical Endocrinology & Metabolism.

- Raun et al. (1998) — Ipamorelin identified as a potent and selective GH secretagogue. Demonstrated no significant effects on ACTH, cortisol, prolactin, FSH, LH, TSH, or GH-binding protein levels.

- Phase II trial (2014) — Ipamorelin studied for postoperative ileus (not fitness). Well tolerated up to 7 days but without clear superiority for the GI endpoint.

- **Clinical trial status: **Neither CJC-1295 nor Ipamorelin are FDA-approved. No active Phase III trials for body composition or anti-aging endpoints.

Key PubMed References

Combination Product

Studies below may reference individual compounds, not this specific combination.

CJC-1295Ipamorelin

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Review

Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026

PMID: 41490200

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.

Review

Lu Z, Ngan MP, Liu JYH, et al. · Physiology & behavior · 2024

PMID: 39043357

Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro.

In Vitro

Jiménez-Reina L, Cañete R, de la Torre MJ, et al. · Histology and histopathology · 2002

PMID: 12168778

The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats.

Animal Study

Andersen NB, Malmlöf K, Johansen PB, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001

PMID: 11735244

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Review

Gobburu JV, Agersø H, Jusko WJ, et al. · Pharmaceutical research · 1999

PMID: 10496658

Anecdotes & Sentiment

Public discussion, not clinical evidence

This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.

No curated public-discussion themes are live for CJC-1295/Ipamorelin yet.

Side Effects & Safety

- **Common: **Injection site reactions (redness, swelling), head rush/flushing shortly after injection, mild headache, water retention, tingling/numbness in extremities - **Less common: **Joint pain (from water retention/GH effects), carpal tunnel-like symptoms, elevated fasting glucose, mild nausea - **Long-term concerns: **Persistent GH/IGF-1 elevation may theoretically increase cancer risk (IGF-1 promotes cell proliferation).

Common: Injection site reactions (redness, swelling), head rush/flushing shortly after injection, mild headache, water retention, tingling/numbness in extremities
Less common: Joint pain (from water retention/GH effects), carpal tunnel-like symptoms, elevated fasting glucose, mild nausea
Long-term concerns: Persistent GH/IGF-1 elevation may theoretically increase cancer risk (IGF-1 promotes cell proliferation). Potential reproductive health impacts with extended use.
Contraindications: Active cancer/malignancy, diabetes (GH can raise blood sugar), pregnancy, pituitary tumors
Drug interactions: Glucocorticoids may blunt GH response. Insulin timing should be coordinated (insulin suppresses GH).

Known Interactions

No curated interaction entry is live for CJC-1295/Ipamorelin yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Comparison Pages

Comparison pages

All

No comparison page is linked yet.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.